Pharmaceutical & Diagnostic Innovation

, Volume 3, Issue 10, pp 16–17 | Cite as

Diagnostic Developments

News & Views

Seeking alternatives to PSA testing

Biomarker panel for diagnosing prostate cancer

Researchers at the University of Michigan Comprehensive Cancer Center have identified a panel of 22 biomarkers that together provide a more accurate screening for prostate cancer than the current prostate-specific antigen (PSA) test.[1] “Initially, we envision this new test could be used as a supplement to PSA. A physician might suggest a patient with an elevated PSA have this test before a biopsy to better determine whether it’s a cancerous or benign condition. In the future, I think this could replace PSA,” commented lead author Professor Arul Chinnaiyan.

The researchers tested blood serum samples from 39 men with prostate cancer and 21 controls to identify autoantibodies against prostate cancer. They scanned 2300 autoantibodies and initially narrowed it down to 186 that reacted with blood serum from men with prostate cancer. This discovery phase formed the basis for the next round of tests, in which...


  1. 1.
    University of Michigan Health System. U-M researchers identify new blood test for prostate cancer. Media release: 22 Sep 2005Google Scholar
  2. 2.
    Ohio State University. Mutation may raise prostate cancer risk in African Americans. Media release: 21 Sep 2005Google Scholar
  3. 3.
    American Cancer Society. Cancer facts and figures for African Americans 2005–2006 [online]. Available at URL: [Accessed 2005 Oct 17]Google Scholar
  4. 4.
    Corgenix Medical. Corgenix launches next generation predictive cardiovascular diagnostic line. Media release: 12 Sep 2005Google Scholar
  5. 5.
    BD Diagnostics. BD Diagnostics announces FDA 510(k) clearance of BD Directigen™ EZ Flu A+B Test. Media release: 22 Sep 2005Google Scholar

Copyright information

© Adis Data Information BV. All rights reserved. 2005

Personalised recommendations